Journal September 16, 2026 5 min read

What is Tirzepatide?

Tirzepatide is a dual GLP-1 and GIP receptor agonist studied in obesity, type 2 diabetes, and a range of metabolic and inflammatory conditions. This page summarises its identifiers, mechanism, and the clinical research l

peptides-pro Editorial

Tirzepatide (LY3298176) is a synthetic peptide that acts as a dual agonist at the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors [6]. It is supplied as a lyophilised powder for laboratory research use. The evidence block for this page does not provide a sequence, molecular formula, or molecular weight, so those identifiers are not stated here.

The research described below centres on incretin receptor signalling — specifically the GLP-1 and GIP receptor families — and its downstream effects on glucose handling, gastric emptying, body weight, and tissue-level inflammation.

Research Studies

Tirzepatide and preoperative optimisation before one anastomosis gastric bypass

A clinical trial is comparing three preoperative strategies before one anastomosis gastric bypass (OAGB) in participants with severe obesity: tirzepatide for 60 days, a ketogenic diet for 4 weeks, or standard care [1]. The primary outcome is weight loss one year after surgery. Secondary outcomes include safety, surgical outcomes, and improvement in obesity-related conditions such as diabetes, high blood pressure, and sleep apnea [1].

Tirzepatide and progestin intrauterine device in endometrial hyperplasia and grade 1 endometrial cancer

A phase II trial is studying whether adding tirzepatide injections to a levonorgestrel intrauterine device (LNG-IUD) improves pathologic response — the absence of cancer cells in tissue samples after treatment — in women with endometrial atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN) or grade 1 endometrial cancer who are overweight or obese [2]. The study notes that endometrial cancer occurrence has continued to rise in the United States, and that over half of cases are thought to be attributable to being overweight and obese, with a weight-dependent risk relationship [2].

Tirzepatide and levonorgestrel IUD therapy for EIN and early-stage endometrial cancer

A separate single-arm study is evaluating the feasibility, safety, and preliminary efficacy of tirzepatide in combination with standard LNG-IUD therapy in patients with endometrial intraepithelial neoplasia (EIN) or grade 1 endometrioid endometrial carcinoma who also have obesity and metabolic risk factors [3]. Participants receive tirzepatide once weekly while continuing standard clinical management with an LNG-IUD, with treatment decisions remaining at the discretion of the treating physician [3]. The primary objective is pathologic response at approximately 6 months; secondary objectives include changes in metabolic parameters [3].

Tirzepatide and real-world outcomes in Pakistani adults with obesity, prediabetes, and type 2 diabetes

A multicentre, prospective, observational study is following 330 adults starting tirzepatide as part of routine clinical care across ten diabetes and endocrinology centres in Pakistan [4]. All participants have obesity and are grouped into three cohorts based on blood sugar status at baseline: obesity without diabetes, prediabetes with obesity, and type 2 diabetes [4]. The study rationale notes that tirzepatide is already approved for type 2 diabetes and for obesity, but that there is very little information on how it works for people in South Asia, and none from Pakistan specifically [4].

Tirzepatide and central centrifugal cicatricial alopecia (CCCA)

A pilot clinical trial is investigating whether tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults [5]. The main questions are whether tirzepatide improves the symptoms and signs of active CCCA, whether it changes the activity of genes in the scalp — especially genes related to scarring — and whether it promotes hair regrowth [5]. Participants inject tirzepatide once a week for 12 months, attend clinic visits for scalp examinations and photographs, and undergo scalp biopsies at baseline and after 6 months of treatment [5].

Tirzepatide and postbariatric hypoglycemia after Roux-en-Y gastric bypass

A case series described 3 patients with postbariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass who were treated with tirzepatide [6]. All patients presented with symptomatic hypoglycemia characterised by episodes of diaphoresis, visual disturbances, confusion, and documented low blood glucose levels occurring postprandially [6]. Conventional management strategies, including dietary modifications, acarbose, and other pharmacotherapies, were either partially effective or limited by side effects [6]. The report describes outcomes following initiation of tirzepatide in this small cohort [6].

Tirzepatide and ileal pouch-anal anastomosis with chronic high bowel frequency

A clinical trial is testing whether tirzepatide (Zepbound) can decrease bowel frequency in patients with an ileal pouch-anal anastomosis (IPAA or pouch) better than standard-of-care anti-diarrheal therapy [7]. The main question is whether tirzepatide reduces bowel frequency better than standard of care in patients with a pouch [7]. Participants attend the clinic 5 times, answer daily symptom questions, take the study product as instructed, and provide stool samples 4 times [7].

Tirzepatide and gastric emptying in type 1 diabetes with overweight or obesity

A study is examining how tirzepatide affects stomach emptying in participants with type 1 diabetes mellitus (T1DM) and overweight or obesity [8]. Participation lasts about 8 weeks, including screening and follow-up [8].

Comparative and discontinuation data

In adults with early uncontrolled type 2 diabetes, tirzepatide versus intensified conventional care reduced HbA1c levels and weight at 2 years [10]. A reconstructed aggregate-data Bayesian longitudinal meta-analysis estimated post-discontinuation weight-regain trajectories after semaglutide or tirzepatide, and explored predictors of faster regain [11]. A comment on a target-trial emulation compared the effectiveness of tirzepatide versus dulaglutide or semaglutide on major cardiovascular events in type 2 diabetes and cardiovascular disease [12]. These reference-only items support the broader research context but are not the focus of this page.

Oral health considerations

A reference-only paper discusses emerging oral health implications of tirzepatide for oral medicine practice [9]. It is noted here as part of the wider literature; no specific findings are reported in the evidence block.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.